{"id":527461,"date":"2021-01-25T13:24:01","date_gmt":"2021-01-25T13:24:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=527461"},"modified":"2021-01-25T13:24:01","modified_gmt":"2021-01-25T13:24:01","slug":"carcinoid-tumor-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/carcinoid-tumor-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast_527461.html","title":{"rendered":"Carcinoid Tumor Market Analysis, Leading Companies, Emerging Drugs and Epidemiology Forecast"},"content":{"rendered":"
\"Carcinoid<\/a><\/p>\n
\n
Delveinsight Business Research LLP<\/p>\n<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Carcinoid Tumor Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Carcinoid Tumor, historical and forecasted epidemiology as well as the Carcinoid Tumor market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<\/div>\n

Carcinoid tumors (CT)<\/strong> are a type of slow-growing cancers that can arise in several places throughout the body and are characterized by the production of an excess of hormone-like substances, such as serotonin, bradykinin, histamine, and prostaglandins which leads to the other associated complications. These tumors are the subset of neuroendocrine tumors and usually begin in the digestive tract (stomach, appendix, small intestine, colon, and rectum) or in the lungs.<\/p>\n

In the terms of their reported occurrence, CT most commonly develops in the gastrointestinal tract. However, they can also occur in other parts of the body such as the lungs, ovaries, or testicles. Based on the location and size of the tumour, CT usually presents with the subset of the symptoms such as cutaneous flushing, itching, and palpitation, edema, salivation, upper body erythema, chronic diarrhoea, malabsorption, and breathing difficulties, etc. <\/p>\n

Get FREE sample copy at: <\/strong>
https:\/\/www.delveinsight.com\/sample-request\/carcinoid-tumor-market<\/strong><\/a>
<\/span><\/p>\n

The Carcinoid Tumor market report<\/strong> also covers emerging drugs, current treatment practices, <\/span>Carcinoid Tumor market share of the individual therapies, current and forecasted Carcinoid Tumor Market Size<\/span> from 2017 to 2030 segmented by seven major markets. <\/span><\/p>\n

The report provides a detailed current Carcinoid Tumor treatment practice\/algorithm<\/strong>, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. <\/span><\/p>\n

 <\/p>\n

\"Carcinoid<\/span><\/p>\n

 <\/p>\n

Carcinoid Tumor Market Key Facts<\/span><\/strong><\/p>\n

As per the study conducted by Siddiqui et al. titled “The Epidemiology of Carcinoid Tumors<\/strong> of Small and Large Intestine in the USA: A National Inpatient Sample Analysis” the malignant CTs of small intestine were the most common out of all CTs of the intestine. Interestingly there was male predominance in CTs of the small intestine and female predominance in CTs of the large intestine.<\/p>\n

The National Organization for Rare Disorders estimates that 27 new cases of Carcinoid Tumour<\/strong> per million are diagnosed in the United States per year out of which, only about 10% develops carcinoid syndrome.<\/p>\n

According to the study titled “Carcinoid syndrome” conducted by Rehman et al., in Japan, the rate of incidence of carcinoid tumors<\/strong> was 5.25 cases per 100,000 in 2004.<\/p>\n

Key Benefits of Carcinoid Tumor Market Report<\/span><\/strong><\/p>\n